Finally, in a Phase I/II study (NCT02275416), ipilimumab (3 mg/kg, every 3 weeks for a total of four doses) in combination with GM-CSF (75 μg) and UV1 peptide based-vaccine directed to hTERT is being tested in unresectable Stage III or Stage IV melanoma patients. This evidence concerns the gene CSF2 and melanoma.